Ptc Therapeutics (PTCT) Change in Receivables (2012 - 2026)

Ptc Therapeutics' Change in Receivables history runs 15 years deep, the most recent figure standing at $40.4 million for Q1 2026.

• On a quarterly basis, Change in Receivables fell 15.49% year-over-year to $40.4 million in Q1 2026; TTM through Mar 2026 was $2.7 million, a 58.09% decrease from a year earlier, with the FY2025 full-year figure at $10.2 million, up 686.09% from the prior year.
• Change in Receivables advanced to $40.4 million in Q1 2026 per PTCT's latest filing, from -$22.2 million in the prior quarter.
• Across five years, Change in Receivables topped out at $47.8 million in Q1 2025 and bottomed at -$40.8 million in Q4 2024.
• The 5-year median for Change in Receivables is $1.2 million (2022), against an average of $5.8 million.
• Across the five-year window, Change in Receivables slumped 2258.37% in 2023 and soared 194.89% in 2024, its largest moves.
• Year by year, Change in Receivables stood at $23.7 million in 2022, then plunged by 135.23% to -$8.3 million in 2023, then slumped by 388.27% to -$40.8 million in 2024, then soared by 45.5% to -$22.2 million in 2025, then surged by 281.82% to $40.4 million in 2026.
• Per Business Quant, the three latest PTCT Change in Receivables figures stand at $40.4 million (Q1 2026), -$22.2 million (Q4 2025), and $6.5 million (Q3 2025).